skelaxin Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Skelaxin, and what generic alternatives are available?

Skelaxin is a drug marketed by King Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SKELAXIN is metaxalone. There are twenty drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the metaxalone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Skelaxin

A generic version of skelaxin was approved as metaxalone by SANDOZ on March 31^st, 2010.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for skelaxin?
What are the global sales for skelaxin?
What is Average Wholesale Price for skelaxin?

Summary for skelaxin

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	119
Patent Applications:	2,531
Drug Prices:	Drug price information for skelaxin
Drug Sales Revenues:	Drug sales revenues for skelaxin
What excipients (inactive ingredients) are in skelaxin?	skelaxin excipients list
DailyMed Link:	skelaxin at DailyMed

Drug patent expirations by year for skelaxin

Paragraph IV (Patent) Challenges for SKELAXIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SKELAXIN	Tablets	metaxalone	800 mg	013217	1	2004-11-04

US Patents and Regulatory Information for skelaxin

skelaxin is protected by one US patents.

Patents protecting skelaxin

Metaxalone products, method of manufacture, and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MUSCULOSKELETAL CONDITIONS

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for skelaxin

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002	⤷ Sign Up	⤷ Sign Up
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002	⤷ Sign Up	⤷ Sign Up
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002	⤷ Sign Up	⤷ Sign Up
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for skelaxin

See the table below for patents covering skelaxin around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007094825		⤷ Sign Up
Canada	2626027	PRODUITS A BASE DE METAXALONE, PROCEDE DE PREPARATION ET PROCEDE D'UTILISATION (METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for skelaxin

Paragraph IV (Patent) Challenges for SKELAXIN

Patents protecting skelaxin

Make Better Decisions: Try a trial or see plans & pricing